Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: journal – Reuters
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
BEIJING (Reuters) – A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emir…
-
Noosa News14 hours agoGippsland vegetable farm accused of underpaying migrant workers
-
General15 hours agoFour escape injury after jumping from three-storey unit on fire in Newcastle
-
General13 hours agoIncreased police powers begin at Adelaide Oval Ashes Test following Bondi attacks
-
Noosa News16 hours agoThe Best Things to Do in Brisbane This New Year’s Eve